Otto Alemán Miranda*

General Clinical and Surgical Hospital Orlando Pantoja Tamayo, Cuba

*Corresponding Author: Otto Alemán Miranda, General Clinical and Surgical Hospital Orlando Pantoja Tamayo, Cuba

Received: July 11, 2023; Published: July 29, 2023

Abstract

The skin is the largest organ of the human body, it fulfills multiple functions that make it an anatomical structure, essential for life. There are multiple conditions that can occur in the buccomaxillofacial complex from a dermatological point of view. This motivated the realization of the present investigation with the objective of describing the main risks and complications in patients with dermatological conditions in the buccomaxillofacial complex. For this, an exhaustive bibliographic review was carried out based on national and international literature, using different descriptors in English and Spanish. The previous experience of the author was taken into account. Then a critical analysis was carried out, where the main risks and complications that may occur in these patients were collected. Dissimilar conditions and the scope of therapeutic procedures performed in these patients with dermatological conditions were illustrated. The content was organized by the different types of dermatological reactions and their main risks. It exposes in a structured and schematic way several of the complications that can occur in these conditions. At the end of the investigation, it is concluded that there are multiple complications and risks to which these patients are exposed, causing functional, mechanical, aesthetic and psychological alterations.

Keywords: Dermatology; Oromaxillofacial Manifestation; Orofacial Dermatology

References

1.  Tincopa Wong OW. “Topical corticosteroids” update and rational use. Dermatological magazine Corticoides tópicos actualización y uso racional. Revista Dermatológica Perú 26.4 (2016). Recuperado (2021).
2. Drake L., et al. “Guidelines of care for the use of topical glucocorticosteroids”. Journal of the American Academy of Dermatology (1996).
3. Guin JD. “Eyelid dermatitis: Experience in 203 cases. (2002)”. Journal of the American Academy of Dermatology 5 (2002): 755-765.
4. García-Fernández D., et al. “Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Skin”.
5. “Stevens-Johnson Syndrome”.Toxic Epidermal Necrolysis Skin. Síndrome de Stevens-Johnson-Necrólisis epidérmica tóxica Piel (2001): 444-451.
6. Gómez A and Sarral de M. “Repelentes de insectos”. Insect repellents. Act Terap Dermatology 21 (1989): 17-22.
7. Williams GH and Dluhy RG. “Enfermedades de la corteza suprarrenal”. Diseases of the adrenal cortex. En: AS. Fauci, E. Braunwald, KJ.Issel bacher (Eds). Harrison principios de medicina interna. Madrid: McGraw-Hill Interamericana (2000): 2312-2327.
8. Biller B and Daniels GH. “Sistema endocrino y metabolismo”. Regulación neuroendocrina y enfermedades de la hipófisis anterior y del hipotálamo. Endocrine system and metabolism. Neuroendocrine regulation and diseases of the anterior pituitary and hypothalamus. En: AS.Fauci, E. Braunwald, KJ.Issel bacher (Eds). Harrison. Principios de medicina interna. Madrid: McGraw-Hill Intermericana (2000): 2241-2271.
9. Quintana A and Raczka E. “Farmacología del sistema endocrino”. Bases farmacológicas. Pharmacology of the endocrine system. Pharmacological bases. En: A. Bascones, P. Bullón, J. Castillo, G. Machuca, FJ. Manso, JS. Serrano (Eds). Bases farmacológicas de la terapéutica odontológica. Madrid: Ediciones avances médico-dentales (2000).
10. Domínguez Espinosa AE., et al. “Correlación clínico-pato1ógica en pénfigos. Clinical-pathological correlation in pemphigus”. Dermatología Revista Mexicana 3 (2001): 117-125.
11. Watts RE. “Porines and nucleotides. En: ED. B Brown, FL. Mitchells, DS. Young (Eds). Clinical diagnoses of disease. Philadelphia: Elsevier North Holland Bio Medical Press (2006).
12. Bittencourt RCA., et al. “Treatment of an-giofibromas with a scanning carbon dioxide laser: a clini-copathologic study with long-term follow-up”. Journal of the American Academy of Dermatology 7 (2001): 31-35.
13. Emmerson BT. “Therapeutics of hyperuricemia and gout”. Medical Journal of Australia 162 (2005): 31-36.
14. Moriwaki S., et al. “Xeroderma pigmentosum -bridginga gap between clinic and laborator”. Photodermatology, Photoimmunology and Photomedicine 2 (2001): 41-54.
15. Norgauer J., et al. “Xeroderma pigmentosum”. European Journal of Dermatology 1 (2003): 4-9.

Citation

Citation: Otto Alemán Miranda. “Risks and Complications in Patients with Oral and Maxillofacial Dermatological Conditions". Acta Scientific Dental Sciences 7.8 (2023): 82-91.

Copyright

Copyright: © 2023 Otto Alemán Miranda. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.